Design Therapeutics, Inc. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2023-02-01

Reporting Person: Siffert Joao MD (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Stock Option (right to buy)	$7.97	A	415000	Acquired	2033-01-31	Common Stock (415000)	Direct

Footnotes

F1: The shares subject to the option will vest as follows: 20% of the shares will vest on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.